Investor Update

Basel, 20 October 2016

Roche delivers good sales growth in the first nine months of 2016

- **Group sales increase 4%[1] at constant exchange rates, 6% in Swiss francs**
- **Pharmaceuticals Division sales up 4%, driven by oncology and immunology medicines**
- **Diagnostics Division sales grow 7%, primarily due to immunodiagnostic products**
- **US FDA approves Tecentriq, the first anti-PD-L1 cancer immunotherapy for metastatic non-small cell lung cancer**
- **Successful launch of cobas e 801, high-throughput immunodiagnostic module**
- **For the eighth year running, Roche ranked as the most sustainable healthcare company in the Dow Jones Sustainability Index (DJSI)**
- **Outlook for 2016 confirmed**

Key figures	**CHFm**		**As % of sales**		**% change**	
January - September	**2016**	**2015**	**2016**	**2015**	**At CER**	**In CHF**
Group sales	37,505	35,525	100	100	+4	+6
Pharmaceuticals Division	29,140	27,690	78	78	+4	+5
United States	13,850	13,047	37	37	+3	+6
Europe	6,916	6,476	18	18	+5	+7
Japan	2,690	2,341	7	7	+0	+15
International*	5,684	5,826	16	16	+4	-2
Diagnostics Division	8,365	7,835	22	22	+7	+7

*Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

[1] Unless otherwise stated, all growth rates in this document are at constant exchange rates (CER: average 2015).

F. Hoffmann-La Roche Ltd
4070 Basel
Switzerland
Investor Relations
email:
investor.relations@roche.com
Tel. +41 61 68-88880
Fax +41 61 69-10014
www.roche.com

Commenting on the Group's first nine months, Roche CEO Severin Schwan said: "We had continued good sales growth in both Pharmaceuticals and Diagnostics driven by our newly launched products, and our product pipeline is developing very well. Our cancer immunotherapy medicine Tecentriq has been performing strongly since May, when it was first approved in the US for people with advanced bladder cancer, and it has just received US FDA approval for previously treated metastatic non-small cell lung cancer. Based on our performance so far, I am confident that we will meet our full-year targets for 2016."

Group

Both divisions showed continued growth

Group sales increased 4% to CHF 37.5 billion. Sales in the Pharmaceuticals Division were up 4% to CHF 29.1 billion, driven by demand for breast cancer medicines Perjeta and Herceptin as well as for Actemra/RoActemra for rheumatoid arthritis. Sales in the US rose 3%, led by three immunology treatments Xolair, Esbriet and Actemra/RoActemra, as well as Activase/TNKase, and Perjeta and Herceptin for HER2-positive breast cancer. The recently launched medicines Tecentriq in bladder cancer and Alecensa in lung cancer have had a strong uptake. US growth was partly offset by a decline in sales of Tamiflu, Lucentis, Avastin and Tarceva. In Europe, sales increased 5% with Perjeta, Actemra/RoActemra and MabThera/Rituxan recording strong growth, especially in Germany and France. In the International region, the 4% growth was driven by the strategic cancer medicines portfolio. In Japan, sales were stable; mandated price cuts for reimbursed products were compensated by strong growth from Alecensa, HER2 cancer medicines and Actemra/RoActemra.

Sales in the Diagnostics Division grew strongly (+7%) to CHF 8.4 billion. All regions contributed to this growth, particularly Asia-Pacific (+17%). Professional, Molecular and Tissue Diagnostics experienced continued good sales development. Diabetes Care sales continue to be impacted by challenging market conditions, especially in North America.

Confirming data for key investigational Roche medicines

Two Roche medicines were granted breakthrough therapy designations (BTD) by the US FDA in October. BTD was granted to Actemra/RoActemra for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune condition. In addition, Alecensa received BTD for the treatment of adult patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor. Also in October, the FDA approved the Lucentis prefilled syringe as a new method of administering the medicine to people with wet age-related macular degeneration and to people with macular edema after retinal vein occlusion.

In September, Roche presented new post-hoc analyses from three pivotal Ocrevus (ocrelizumab) studies at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The new data showed that Ocrevus consistently increased disease control both in patients with the relapsing form of multiple sclerosis and in those with the primary progressive form.

At the European Society for Medical Oncology (ESMO) annual meeting in October, Roche presented results from the phase III OAK trial with Tecentriq in metastatic NSCLC. The study met its primary endpoint, having established a survival benefit over chemotherapy, even in people with low or no observed levels of PD-L1 expression. These results add to the growing body of evidence that supported the FDA approval of Tecentriq as a new treatment for specific types of advanced NSCLC. In addition to OAK, Roche has seven phase III lung studies underway evaluating Tecentriq alone or in combination with other treatments in patients with early and advanced stages of lung cancer.

Portfolio progress in Diagnostics

In August, the FDA granted a premarket clearance and CLIA (Clinical Laboratory Improvement Amendments) waiver for the cobas Influenza A/B & RSV test for use on the cobas Liat System. This test also identifies the Respiratory Syncytial Virus (RSV), which causes more than 80% of acute lower respiratory tract infections in infants under one year old. The FDA also issued an Emergency Use Authorization for the LightMix Zika rRT-PCR test for use in patients meeting clinical and/or epidemiological criteria developed by the Center for Disease Control. These tests further expand the rich menu of Roche products.

Also in August, the Accu-Chek Guide was launched in the EU. This next-generation blood glucose monitoring system is designed to make everyday blood glucose monitoring easier for people with diabetes. The Accu-Chek Guide system also provides advanced accuracy, which enables reliable diabetes management.

Roche the most sustainable healthcare company

The Dow Jones Sustainability Index (DJSI) recognised Roche as the most sustainable company in the healthcare industry for the eighth consecutive year. This year’s DJSI assessment emphasised that by focusing on access to healthcare, compliance and transparency, a diverse work culture and collaboration with a variety of partners, Roche is committed to creating value for all its stakeholders.

Outlook for 2016 confirmed

Roche expects sales to grow low- to mid-single digit at constant exchange rates in 2016. Core earnings per share are targeted to grow ahead of sales at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

Pharmaceuticals Division

Top-selling	Total		United States		Europe		Japan		International*	
pharmaceuticals	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
MabThera/Rituxan	5,484	3	2,933	1	1,429	4	211	11	911	5
Herceptin	5,125	5	1,898	3	1,569	3	225	4	1,433	8
Avastin	5,114	1	2,261	-4	1,402	2	611	-1	840	19
Perjeta	1,379	31	683	13	473	54	77	10	146	86
Actemra/RoActemra	1,247	17	474	16	416	19	205	12	152	17
Xolair	1,120	17	1,120	17	-	-	-	-	-	-
Lucentis	1,077	-8	1,077	-8	-	-	-	-	-	-
Activase/TNKase	807	16	773	17	-	-	-	-	34	9
Tarceva	765	-16	412	-16	135	-21	76	-2	142	-19
Kadcyla	616	9	238	1	250	5	55	16	73	51

Herceptin, Perjeta and **Kadcyla** (combined +9%). For HER2-positive breast cancer and HER2-positive metastatic gastric cancer (Herceptin only). **Herceptin** sales grew 5%, driven by growing demand in the US and Europe and expanded reimbursement in additional provinces in China. **Perjeta** (+31%) performed well, mainly due to uptake in the neoadjuvant setting and continued strong growth in the metastatic setting. **Kadcyla** sales (+9%) were fuelled by increasing demand in the International region and in Europe.

MabThera/Rituxan (+3%). For common forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Sales continued to grow despite competitive pressure. Increasing demand was seen in Europe, China and Japan. Market share is already high in the US, where sales grew 1%.

Avastin (+1%). For advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, and relapsed glioblastoma (a type of brain tumour). Sales continued to grow strongly in the International region (+19%), especially China, where sales increased following improved access in the lung cancer setting. In Europe, sales grew 2% as a result of increasing use in colorectal and breast cancer, in particular in Germany. Sales in the US, where Avastin is already being broadly used in its approved indications, declined 4%.

Gazyva/Gazyvaro (+54%). For the treatment of chronic lymphocytic leukemia (CLL) and rituximab-refractory follicular lymphoma. Growth was seen in the US and Europe despite increasing competition in CLL. Gazyva/Gazyvaro is now approved for CLL in more than 75 countries. Following US and EU approval of the medicine in previously treated follicular lymphoma in the first half of 2016, uptake for this indication has been encouraging.

Actemra/RoActemra (+17%). For rheumatoid arthritis and forms of juvenile idiopathic arthritis. Increasing use of Actemra/RoActemra as a single agent, and of the subcutaneous formulation, remained key growth drivers globally. Following the recent FDA BTD awarded to this medicine in GCA, Roche will present phase III study data in this disease area for the first time at the annual meeting of the American College of Rheumatology (ACR) this year.

Esbriet (+45%). For idiopathic pulmonary fibrosis (IPF). Sales continued to grow with most uptake in patients with more moderate and progressive disease. Significant potential still remains in patients with a less advanced form of the disease.

All recently launched medicines showed good sales performance. **Alecensa** (CHF 122 million) is for people with ALK-positive advanced NSCLC whose disease has progressed on, or who are intolerant to crizotinib. There has been very good initial uptake in the US. Sales growth remained strong in Japan, where the medicine was launched in 2014 for a broader patient population, i.e. including people who have not received prior treatment with crizotinib. **Cotellic** (CHF 30 million) plus Zelboraf for metastatic melanoma showed good sales uptake, especially in major markets such as France, Germany and the US. Following FDA accelerated approval of **Tecentriq** (CHF 77 million) in locally advanced or metastatic urothelial carcinoma in May, initial market uptake in the US has been strong.

Diagnostics Division

Sales January - September		CHFm	% change At CER	 In CHF	As % of sales
Sales - Diagnostics Division		8,365	+7	+7	100
Business Areas	Professional Diagnostics	4,884	+9	+9	58
	Diabetes Care	1,484	-2	-3	18
	Molecular Diagnostics	1,345	+7	+8	16
	Tissue Diagnostics	652	+13	+15	8
Regions	Europe, Middle East, Africa	3,406	+2	+2	41
	North America	2,211	+4	+7	26
	Asia–Pacific	1,847	+17	+15	22
	Latin America	567	+21	+4	7
	Japan	334	+2	+17	4

Professional Diagnostics (+9%) was the largest contributor to the division's sales growth, led by the Asia-Pacific region, with continued strong growth in China (+24%). The immunodiagnostics business saw strong growth (+14%) and clinical chemistry sales increased 6%.

The new cobas e 801 high-throughput immunodiagnostic module had very good market uptake; it was launched in June 2016 in countries accepting the CE Mark. As part of the cobas 8000 analyser, this module provides increased immunochemistry testing capacity and an extensive test menu. The continued strong performance of the immunodiagnostics business reflects the wide range of solutions Roche offers to the core laboratories.

Molecular Diagnostics sales increased 7%, led by the Asia-Pacific region. The main growth contributors were the sequencing and molecular businesses. The molecular business growth was driven by virology (+11%), including the diagnosis and monitoring of hepatitis and HIV viral load as well as HPV screening (+13%).

The strong sales performance was based on the comprehensive portfolio of modern instrumentation combined with the very broad test portfolio which Roche offers. The addition of the cobas Influenza A/B & RSV on the cobas Liat System and the LightMix Zika rRT-PCR tests further expanded this base.

Tissue Diagnostics sales increased 13%, driven by sales in North America. Sales in the advanced staining portfolio grew 9% and sales in primary staining increased 18%. Revenue from external personalised healthcare partnerships also showed continued strong growth (+39%).

Diabetes Care sales decreased 2%, predominantly due to continued price pressure in the US. Increasing sales were recorded in Latin America, while EMEA and Asia-Pacific regional sales were slightly down.

Nine Months Sales 2016 Conference Call

There will be a conference call for investors and analysts today, **Thursday, 20 October at 2:00 pm CEST**. Please dial in to the conference call 10-15 min. prior to the scheduled start, using the following numbers:

+41 (0) 58 310 5000 (Europe and ROW)
+44 (0) 203 059 5862 (UK)
+1 (1) 631 570 5613 (USA)

Alternatively a **live audio webcast** can be accessed via http://ir.roche.com.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in *in vitro* diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the

Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Index.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Additional information

- Nine Months 2016 Sales Presentation with appendix: http://www.roche.com/irp161020.pdf
- Nine Months 2016 Sales Presentation: http://www.roche.com/irp161020-a.pdf
- Pharmaceuticals: major clinical and regulatory news-flow in 2016: http://www.roche.com/pharma3q16e.pdf
- Diagnostics: key diagnostics product launches in 2016: http://www.roche.com/dia3q16e.pdf
- Finance Report Half Year 2016: www.roche.com/annual_reports
- Roche Annual Report 2015 (includes corporate responsibility report): www.roche.com/annual_reports
- Dow Jones Sustainability Indices: http://www.sustainability-indices.com

Roche Investor Relations

Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Tamer Farhan
Phone: +41 61 68-82552
e-mail: tamer.farhan@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com

Investor Relations North America

Neera Dahiya Ravindran, MD
Phone: +1 650 491 5281
e-mail: ravindran.neera@gene.com

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Disclaimer: Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for 2015 or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Appendix: Tables

1. Sales January to September 2016 and 2015

CHF millions	Nine months ended 30 September		% change	
	2016	2015	At CER	In CHF
Pharmaceuticals Division	29,140	27,690	4	5
United States	13,850	13,047	3	6
Europe	6,916	6,476	5	7
Japan	2,690	2,341	0	15
International*	5,684	5,826	4	-2
Diagnostics Division	8,365	7,835	7	7
Roche Group	37,505	35,525	4	6

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

2. Quarterly sales and constant exchange rate sales growth by Division in 2016 and 2015

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
Pharmaceuticals Division	9,340	6	9,641	3	9,800	4	9,660	5	9,680	2
United States	4,461	7	4,569	3	4,716	3	4,557	5	4,577	1
Europe	2,185	6	2,258	5	2,319	5	2,320	6	2,277	5
Japan	801	8	883	2	853	4	903	1	934	-3
International*	1,893	4	1,931	2	1,912	4	1,880	5	1,892	2
Diagnostics Division	2,600	4	2,979	7	2,614	5	2,948	8	2,803	8
Roche Group	11,940	6	12,620	4	12,414	4	12,608	6	12,483	3

*Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

3. Pharmaceuticals Division

Top-selling pharmaceuticals and recent new launches	Total		United States		Europe		Japan		International*	
January - September 2016	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	5,484	3	2,933	1	1,429	4	211	11	911	5
Herceptin	5,125	5	1,898	3	1,569	3	225	4	1,433	8
Avastin	5,114	1	2,261	-4	1,402	2	611	-1	840	19
Perjeta	1,379	31	683	13	473	54	77	10	146	86
Actemra/RoActemra	1,247	17	474	16	416	19	205	12	152	17
Xolair	1,120	17	1,120	17	-	-	-	-	-	-
Lucentis	1,077	-8	1,077	-8	-	-	-	-	-	-
Activase/TNKase	807	16	773	17	-	-	-	-	34	9
Tarceva	765	-16	412	-16	135	-21	76	-2	142	-19
Kadcyla	616	9	238	1	250	5	55	16	73	51
Recent new launches										
Esbriet	571	45	419	56	135	25	-	-	17	-7
Zelboraf	160	2	35	4	92	-3	3	-2	30	17
Erivedge	148	25	97	13	39	48	-	-	12	68
Gazyva	142	54	87	55	38	156	-	-	17	-19
Alecensa	122	174	47	-	1	**	74	60	-	-
Tecentriq	77	-	76	-	1	-	-	-	-	-
Cotellic	30	-	8	-	22	-	-	-	-	-

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others
** Over 500%

4. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD September 2016 vs. YTD September 2015

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	5,484	3	2,933	1	1,429	4	211	11	911	5
Herceptin	5,125	5	1,898	3	1,569	3	225	4	1,433	8
Avastin	5,114	1	2,261	-4	1,402	2	611	-1	840	19
Perjeta	1,379	31	683	13	473	54	77	10	146	86
Actemra/RoActemra	1,247	17	474	16	416	19	205	12	152	17
Xolair	1,120	17	1,120	17	-	-	-	-	-	-
Lucentis	1,077	-8	1,077	-8	-	-	-	-	-	-
Activase/TNKase	807	16	773	17	-	-	-	-	34	9
Tarceva	765	-16	412	-16	135	-21	76	-2	142	-19
Kadcyla	616	9	238	1	250	5	55	16	73	51
Esbriet	571	45	419	56	135	25	-	-	17	-7
CellCept	559	-5	134	-11	132	-1	51	13	242	-6
Pulmozyme	504	6	349	4	91	7	-	-	64	15
Tamiflu	503	-9	326	-23	38	211	76	25	63	13
Mircera	375	-4	-	-	65	-3	156	1	154	-9
Xeloda	350	-10	27	-40	25	-24	82	12	216	-8
NeoRecormon/Epogin	244	-10	-	-	107	-9	34	-13	103	-10
Rocephin	232	13	1	-	26	-10	21	-13	184	20
Valcyte/Cymevene	227	-15	52	-9	90	-23	-	-	85	-10
Madopar	214	6	-	-	74	1	12	-5	128	10

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
MabThera/Rituxan	1,772	4	1,777	4	1,825	3	1,877	5	1,782	0
Herceptin	1,614	7	1,659	10	1,725	4	1,709	5	1,691	4
Avastin	1,705	8	1,716	9	1,706	4	1,724	4	1,684	-3
Perjeta	376	57	410	50	439	33	467	35	473	24
Actemra/RoActemra	367	18	390	25	386	14	428	21	433	15
Xolair	339	21	345	22	356	22	375	17	389	13
Lucentis	373	-18	378	-17	355	-13	349	-10	373	-1
Activase/TNKase	239	14	259	36	276	21	261	17	270	12
Tarceva	292	-7	287	-9	258	-14	262	-17	245	-18
Kadcyla	196	44	211	36	201	11	207	10	208	5
Esbriet	157	-	177	296	178	96	180	24	213	35
CellCept	194	-4	203	13	189	-4	184	-5	186	-5
Pulmozyme	166	14	180	8	160	7	177	10	167	0
Tamiflu	118	46	170	-67	367	-6	43	5	93	-23
Mircera	147	55	106	-1	118	0	123	7	134	-16
Xeloda	124	-11	129	-9	111	-17	119	-5	120	-6
NeoRecormon/Epogin	90	-8	94	-6	79	-14	82	-8	83	-7
Rocephin	64	-8	73	-1	82	5	75	18	75	18
Valcyte/Cymevene	83	-52	99	-41	78	-21	82	-6	67	-18
Madopar	70	10	71	-9	71	20	69	-4	74	4

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
MabThera/Rituxan	947	4	938	7	978	0	1,023	6	932	-3
Herceptin	609	12	599	13	651	4	630	6	617	0
Avastin	784	6	772	11	775	-2	763	0	723	-9
Perjeta	208	37	217	31	224	15	230	16	229	8
Actemra/RoActemra	144	21	153	32	145	12	164	23	165	13
Xolair	339	21	345	22	356	22	375	17	389	13
Lucentis	373	-18	378	-17	355	-13	349	-10	373	-1
Activase/TNKase	228	15	246	36	265	21	250	18	258	12
Tarceva	159	-7	160	1	136	-15	141	-17	135	-16
Kadcyla	79	6	79	12	79	-2	80	7	79	-1
Esbriet	114	-	124	**	127	145	134	32	158	38
CellCept	53	-14	54	29	45	0	43	-18	46	-13
Pulmozyme	115	9	128	19	112	6	121	7	116	0
Tamiflu	104	54	121	-74	251	-15	12	-45	63	-39
Mircera	-	-	-	-	-	-	-	-	-	-
Xeloda	12	3	13	13	5	-71	12	-24	10	-21
NeoRecormon/Epogin	-	-	-	-	-	-	-	-	-	-
Rocephin	-	-	-	-	-	-	-	-	1	-
Valcyte/Cymevene	16	-86	33	-64	19	-25	19	15	14	-10
Madopar	-	-	-	-	-	-	-	-	-	-

** Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
MabThera/Rituxan	455	1	468	3	479	5	482	5	468	4
Herceptin	502	0	510	4	525	2	523	3	521	4
Avastin	457	5	465	5	471	2	473	4	458	-1
Perjeta	114	96	130	74	149	65	161	56	163	42
Actemra/RoActemra	120	19	129	23	131	17	143	21	142	18
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	54	-20	52	-23	48	-18	44	-27	43	-19
Kadcyla	83	92	88	49	83	13	84	2	83	1
Esbriet	37	-	46	44	45	36	41	9	49	33
CellCept	44	-10	47	-1	43	-3	46	2	43	-1
Pulmozyme	29	8	30	8	31	6	30	5	30	10
Tamiflu	1	-65	3	455	20	78	11	**	7	**
Mircera	21	-1	22	-4	21	-7	22	-2	22	0
Xeloda	10	-41	10	-30	9	-31	8	-17	8	-23
NeoRecormon/Epogin	38	-9	38	-6	36	-10	35	-11	36	-7
Rocephin	5	-15	9	-27	13	-13	7	-13	6	2
Valcyte/Cymevene	39	-1	36	-16	30	-26	30	-21	30	-21
Madopar	24	2	24	-1	24	-1	25	2	25	2

** Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
MabThera/Rituxan	59	7	64	9	62	12	72	12	77	9
Herceptin	65	3	70	3	67	5	79	4	79	2
Avastin	189	13	208	12	192	7	206	-2	213	-6
Perjeta	22	18	23	14	23	18	27	10	27	4
Actemra/RoActemra	57	13	61	10	60	14	70	13	75	10
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Tarceva	25	12	24	-1	22	0	27	3	27	-9
Kadcyla	15	39	16	23	17	27	20	20	18	4
Esbriet	-	-	-	-	-	-	-	-	-	-
CellCept	14	11	16	11	15	11	18	16	18	12
Pulmozyme	-	-	-	-	-	-	-	-	-	-
Tamiflu	-	-	12	-75	60	4	4	**	12	**
Mircera	48	6	54	9	45	4	55	2	56	-1
Xeloda	22	8	25	10	25	12	29	16	28	8
NeoRecormon/Epogin	12	-7	12	-9	10	-12	12	-12	12	-16
Rocephin	8	-2	7	-5	6	-10	7	-19	8	-11
Valcyte/Cymevene	-	-	-	-	-	-	-	-	-	-
Madopar	4	-2	4	-2	3	-7	5	-2	4	-6

** Over 500%

9.Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q3 2015	% change vs. Q3 2014	Q4 2015	% change vs. Q4 2014	Q1 2016	% change vs. Q1 2015	Q2 2016	% change vs. Q2 2015	Q3 2016	% change vs. Q3 2015
MabThera/Rituxan	311	5	307	-2	306	11	300	3	305	0
Herceptin	438	9	480	16	482	7	477	8	474	10
Avastin	275	16	271	7	268	27	282	18	290	14
Perjeta	32	125	40	131	43	65	49	121	54	78
Actemra/RoActemra	46	15	47	31	50	10	51	23	51	18
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	11	-11	13	32	11	13	11	3	12	12
Tarceva	54	-1	51	-18	52	-14	50	-15	40	-27
Kadcyla	19	74	28	93	22	56	23	53	28	44
Esbriet	6	-	7	114	6	4	5	-8	6	-17
CellCept	83	5	86	16	86	-8	77	-4	79	-4
Pulmozyme	22	49	22	-22	17	22	26	38	21	-12
Tamiflu	13	22	34	73	36	35	16	9	11	-24
Mircera	78	206	30	-13	52	0	46	18	56	-29
Xeloda	80	-11	81	-12	72	-13	70	-6	74	-6
NeoRecormon/Epogin	40	-8	44	-5	33	-18	35	-5	35	-5
Rocephin	51	-7	57	0	63	12	61	30	60	22
Valcyte/Cymevene	28	-17	30	-22	29	-14	33	2	23	-18
Madopar	42	17	43	-13	44	39	39	-7	45	6

* Asia–Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, Others